help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allan, G. F.
Right arrow Articles by Phillips, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allan, G. F.
Right arrow Articles by Phillips, A.

Molecular Endocrinology, Vol 10, 1206-1213, Copyright © 1996 by Endocrine Society


ARTICLES

Induction of a novel conformation in the progesterone receptor by ZK299 involves a defined region of the carboxyl-terminal tail

GF Allan, E Lombardi, D Haynes-Johnson, S Palmer, M Kiddoe, P Kraft, C Campen, P Rybczynski, DW Combs and A Phillips
Department of Reproductive Medicine, R. W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869, USA.

Progesterone receptor antagonists are a promising class of therapeutic drugs indicated for the treatment of a variety of reproductive conditions. Understanding their mechanism of action at the molecular level is an important prerequisite for the development of future generations of these drugs. Using limited proteolytic analysis to monitor conformational changes in the progesterone receptor, we can detect three distinct classes of progestin antagonist. The effect of the first, RU486, on the conformation of the carboxyl terminus of the receptor has been previously described. The second, exemplified by RWJ 47626, a nonsteroidal compound with in vitro antiprogestin activity, induces a proteolytic fragment pattern indistinguishable from that induced by the agonist R5020. Finally, ZK299 induces a fragment pattern intermediate between that induced by R5020 and RU486. Site-directed mutagenesis of the carboxyl-terminal tail of the progesterone receptor indicates that the region containing the putative activation function AF-2 is differentially exposed to proteolytic attack depending on the nature of the antagonist bound. The differentially exposed region is most accessible when the antagonist RU486 is bound, less accessible when the antagonist ZK299 is bound, and least accessible when the antagonist RWJ47626 or agonist R5020 is bound. The results suggest that multiple types of antiprogestin can be defined in terms of their effects on the conformation of the carboxyl-terminal activation function of the progesterone receptor.


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
Z. Liu, D. Auboeuf, J. Wong, J. D. Chen, S. Y. Tsai, M.-J. Tsai, and B. W. O'Malley
Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486
PNAS, June 11, 2002; 99(12): 7940 - 7944.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. A. Leonhardt, M. Altmann, and D. P. Edwards
Agonist and Antagonists Induce Homodimerization and Mixed Ligand Heterodimerization of Human Progesterone Receptors in Vivo by a Mammalian Two-Hybrid Assay
Mol. Endocrinol., December 1, 1998; 12(12): 1914 - 1930.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
E. K. Gass, S. A. Leonhardt, S. K. Nordeen, and D. P. Edwards
The Antagonists RU486 and ZK98299 Stimulate Progesterone Receptor Binding to Deoxyribonucleic Acid in Vitro and in Vivo, but Have Distinct Effects on Receptor Conformation
Endocrinology, April 1, 1998; 139(4): 1905 - 1919.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
B. L. Wagner, J. D. Norris, T. A. Knotts, N. L. Weigel, and D. P. McDonnell
The Nuclear Corepressors NCoR and SMRT Are Key Regulators of Both Ligand- and 8-Bromo-Cyclic AMP-Dependent Transcriptional Activity of the Human Progesterone Receptor
Mol. Cell. Biol., March 1, 1998; 18(3): 1369 - 1378.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
C. J. Fryer, S. K. Nordeen, and T. K. Archer
Antiprogestins Mediate Differential Effects on Glucocorticoid Receptor Remodeling of Chromatin Structure
J. Biol. Chem., January 9, 1998; 273(2): 1175 - 1183.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. J. Modarress, J. Opoku, M. Xu, N. J. Sarlis, and S. S. Simons Jr.
Steroid-induced Conformational Changes at Ends of the Hormone-binding Domain in the Rat Glucocorticoid Receptor Are Independent of Agonist Versus Antagonist Activity
J. Biol. Chem., September 19, 1997; 272(38): 23986 - 23994.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. J. Fryer, H. K. Kinyamu, I. Rogatsky, M. J. Garabedian, and T. K. Archer
Selective Activation of the Glucocorticoid Receptor by Steroid Antagonists in Human Breast Cancer and Osteosarcoma Cells
J. Biol. Chem., June 2, 2000; 275(23): 17771 - 17777.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society